1Groszmann R, Vorobioff JD. Measurement of portal pres- sure: When, How, and Why to do it[J]. Clin Liver Dis, 2006, (10) : 499 -512. 被引量：1
2Triantos CK, Nikolopoulou V, Burroughs AK. Review article: the therapeutic and prognostic benefit of portal pressure re- duction in cirrhosis [ J ]. Aliment Pharmacol Ther, 2008, 28 (8) :943 -952. 被引量：1
3Burroughs AK, Thalheimer U. Hepatic venous pressure gra- dient in 2010 . optimal measurement is key[ J ] . Hepatology, 2010, 51 (6) :1894 -1896. 被引量：1
4Abraldes JG, Tarantinol, Turnes J, et al. Hemodynamic re- sponse to pharmacological treatment of portal hypertension and long -term prognosis of cirrhosis [ J ]. Hepatology, 2003, 37(4) :902 -908. 被引量：1
5Ripoll C, Groszmann R, Garcia -Tsao G, et al. Hepatic ve- nous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis [ J ]. Gastroenterology, 2007, 133(2) : 481 -488. 被引量：1
6Rockey DC, Friedman SL. Hepatic fibrosis and cirrhosis in BoyerTD, Manns MP, Sanyal AJ eds, Zakim & Boyer' s Hepatology 6th ELSEVER Philadelphia USA, 2012: 77. 被引量：1
7Guadalupe Garcia - TsaoHepatic Venous Pressure Gradient, Biopsy or Both? In Roberto de Franchised. Portal Hyperten- sion V, 5th edition. Blackwell Publishing Ltd, 2011 :9 -17. 被引量：1
8Kalambokis G, Manousou P, Samonakis D, et al. Clinical outcome of HCV - related graft cirrhosis and prognostic value of hepatic venous pressure gradient[ J]. Transpl Int, 2009, 22(2): 172 -181. 被引量：1
9Blasco A, Forns X, Carrion JA, et al. Hepatic venous pres- sure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplan - tation [ J ]. Hepatology, 2006, 43(3) :492 -499. 被引量：1
10Vibhakorn S, Cholongitas E, Kalambokis G, et al. A compari- son of four - versus three -pass transjugular biopsy using a 19 -G Tru -Cut needle and a randomized study using a cas- sette to prevent biopsy fragmentation [ J ]. Cardiovasc Inter- vent Radiol, 2009, 32(3) : 508 -513. 被引量：1
4GROSZMANN R J, GARCIA -TSAO G, BOSCH J, et al. Beta - blockers to prevent gastroesophageal varices in patients with cirrhosis[J]. N Engl J Med, 2005, 353(21 ) : 2254 -2261. 被引量：1
5D' AMICO G, GARCIA - PAGAN JC, LUCA A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review[ J]. Gastroenterol- ogy, 2006, 131 (5) : 1624. 被引量：1
6MEJIAS M, GARCIA -PRAS E, TIANI C, et al. The soma- tostatin analogue octreotide inhibits angiogenesis in the earli- est, but not in advanced, stages of portal hypertension in rats[J]. J Cell Mol Med, 2008, 12(5A) : 1690 -1699. 被引量：1
7CHAN MM, CHAN MM, MENGSHOL JA, et al. Octreotide: a drug often used in the critical care setting but not well un- derstood[J]. Chest, 2013, 144(6) : 1937 -1945. 被引量：1
8WANG J, WANG L, SONG G, et al. The mechanism through which octreotide inhibits hepatic stellate cell activity [J ]. Mol Med Rep, 2013, 7(5) : 1559 -1564. 被引量：1
9VILLANUEVA C, PLANELLA M, ARACIL C, et al. Hemody- namic effects of terlipressin and high somatostatin dose dur-ing acute variceal bleeding in matostatin dose [ J ]. Am J nonresponders to the usual so- Gastroenterol, 2005, 100 ( 3 ) : 624 -630. 被引量：1
10NARAHARA Y, KANAZAWA H, TAKI Y, et al. Effects of ter- lipressin on systemic, hepatic and renal hemodynamics in pa- tients with cirrhosis [ J ]. J Gastroenterol Hepatol, 2009, 24 (11) : 1791 -1797. 被引量：1
